Ventyx Biosciences Inc (VTYX)
2.88
+0.01
(+0.35%)
USD |
NASDAQ |
Jun 14, 16:00
2.88
0.00 (0.00%)
After-Hours: 20:00
Ventyx Biosciences Cash from Investing (Quarterly): 41.76M for March 31, 2024
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 41.76M |
| December 31, 2023 | 46.12M |
| September 30, 2023 | 38.89M |
| June 30, 2023 | 34.82M |
| March 31, 2023 | -18.90M |
| December 31, 2022 | -140.84M |
| September 30, 2022 | 64.16M |
| Date | Value |
|---|---|
| June 30, 2022 | 18.25M |
| March 31, 2022 | -16.50M |
| December 31, 2021 | -143.09M |
| September 30, 2021 | -73.16M |
| June 30, 2021 | -0.011M |
| March 31, 2021 | 1.899M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-143.09M
Minimum
Dec 2021
64.16M
Maximum
Sep 2022
-11.28M
Average
1.899M
Median
Mar 2021
Cash from Investing (Quarterly) Benchmarks
| Anavex Life Sciences Corp | -- |
| Checkpoint Therapeutics Inc | -- |
| Altimmune Inc | -39.52M |
| Viking Therapeutics Inc | -459.79M |
| vTv Therapeutics Inc | -- |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -47.62M |
| Cash from Financing (Quarterly) | 96.18M |
| Free Cash Flow | -183.86M |
| Free Cash Flow Per Share (Quarterly) | -0.7731 |
| Free Cash Flow Yield | -107.1% |